On December 1, 2022, the FDA approved another IDH1 inhibitor, OLU [89], for use in R/R AML based on a phase 1/2 trial of patients with IDH1-mutant R/R AML who were naïve to IDH1 inhibitors [90]. The gene discussed is IDH1; the disease is acute myeloid leukemia.